key: cord-1020805-eq6rov82
authors: Lechien, Jerome R.; Hopkins, Claire; Saussez, Sven
title: Letter to the Editor about the Beltrán‐Corbellini et al. publication :"Acute‐onset smell and taste disorders in the context of Covid‐19: a pilot multicenter PCR‐based case‐control study" (Eur J Neurol. 2020. doi: 10.1111/ene.14273.)
date: 2020-05-22
journal: Eur J Neurol
DOI: 10.1111/ene.14357
sha: 206f25a184662b7fc794e9b99dcee1a342da8951
doc_id: 1020805
cord_uid: eq6rov82

We read, with interest, the paper entitled "Acute‐onset smell and taste disorders in the context of Covid‐19: a pilot multicenter PCR‐based case‐control study". The authors observed that sudden loss of smell (LOS) was significantly more frequent in Covid‐19 patients (39%) than those infected with influenza (12%). These data corroborated the results of Yan et al.

PROFESSOR SVEN SAUSSEZ (Orcid ID : 0000-0002-3655-1854) Article type : Letters to the Editor Dear editor, We read, with interest, the paper entitled "Acute-onset smell and taste disorders in the context of Covid-19: a pilot multicenter PCR-based case-control study". 1 The authors observed that sudden loss of smell (LOS) was significantly more frequent in Covid-19 patients (39%) than those infected with influenza (12%). These data corroborated the results of Yan et al. who reported that LOS concerned 71% and 17% of positive and negative covid-19 patients with influenza-like symptoms, respectively. 2 The assessment of LOS was made through a patient questionnaire.

Their paper raises several points. First, the authors reported a prevalence of 5 to 48% of LOS in the current literature. However, recent European and American large case-series reported that the LOS incidence would be higher than presumed by Beltrán-Corbellini et al., reporting rates of 66% and 70% of mild cases of COVID-19 infection. 2, 3 Second, the authors rejected the use of objective olfactory evaluations, due to concerns of contamination and unnecessary burden on both physician and patient, may be . However, emerging evidence suggests that there may be a mismatch between the rate of self-reported LOS of patients and the prevalence of anosmia and hyposmia according to psychophysical olfactory testings. 4, 5 Thus, in a cohort of 46 patients reporting LOS, the objective olfactory testing found 52% and 24% of anosmic and hyposmic individuals. In other words, 24% of patients with LOS did not have olfactory dysfunctions. 4 In contrast, in a recent clinical series, Moien et al. showed that 98% of covid-19 patients presented an objective LOS while only 38% self-reported LOS. 5 These studies highlight the importance of including objective testing in planning future studies. To reduce the risk of contamination or exposition for physicians, a system of mobile testing unit with limited olfactory stick tests may help. 4

This article is protected by copyright. All rights reserved Third, many patients infected with influenza were contacted by telephone two months after discharge; which raises the possibility of underestimation of LOS in this group of patients due to recall bias.

Interestingly, the authors reported only 13% of patients had nasal obstruction 1 while we observed up to 68% nasal obstruction in our series of 1,420 patients with a mild form of COVID-19 infection. 3 Although the high frequency of nasal obstruction, there was no statistically significant correlation between anosmia and nasal obstruction, indirectly supporting the occurrence of damage in the olfactory neuroepithelium.

Finally, we fully share the author conclusion suggesting the imperative to add LOS to the list of symptoms of COVID-19 infection. We have previously stressed the need to consider initial and sudden LOS as a specific symptom of COVID-19. France, Switzerland and U.S. already adopted this point, but the World Health Organization has not yet updated their criteria. . Use of self-reported loss of smell and taste as a marker of infection will be a very useful weapon in the COVID-19 fight, especially in countries with emerging pandemics where access to testing will be greatly limited.

Accepted Article

Acute-onset smell and taste disorders in the context of Covid-19: a pilot multicenter PCR-based case-control study

Self-reported olfactory loss associates with outpatient clinical course in Covid-19. Int Forum Allergy Rhinol

Clinical and Epidemiological Characteristics of 1,420 European Patients with mild-to-moderate Coronavirus Disease

Objective olfactory testing in patients presenting with sudden onset olfactory dysfunction as the first manifestation of confirmed COVID-19 infection

Smell dysfunction: a biomarker for COVID-19. Int Forum Allergy Rhinol

Accepted Article